View this email in your browser ([link removed])
[link removed]
[link removed]

Your source for the latest news in drug policy. Visit our website ([link removed]) for more news.

A recent study ([link removed]) in JAMA Network Open found that the population-attributable fraction ([link removed].) of cannabis use disorder (CUD) that was associated with schizophrenia in Ontario, Canada, increased from 3.7% prior to the legalization of marijuana to 10.3% after legalization. This represented a statistically significant increase.

The authors explained that this increase occurred alongside Canada’s liberalization of marijuana laws. Drawing on various sources, they added:
* The potency of marijuana doubled over the study’s time frame; more than 70% of dried marijuana that is sold in Ontario now exceeds 20% THC.
* Emergency department visits in Ontario for cannabis-induced psychosis and CUD have increased.
* Between 2006 and 2022, the percentage of Ontario residents aged 18 years or older who reported past-year cannabis use and patterns placing them at moderate or high risk of experiencing social problems or cannabis dependence increased by 145.5% and 223.3%, respectively.

The authors noted, “Our results, and those of others, highlight that the association between CUD and schizophrenia may be particularly elevated among younger males, in whom an estimated 18.9% of incident schizophrenia cases were associated with CUD by the end of the study.”

Dr. Daniel Myran, the study’s first author and an affiliate of the University of Ottawa, said in a statement ([link removed]) , “The tripling of schizophrenia cases associated with a cannabis use disorder over the past 17 years and rising cases of psychosis underscores the urgent need for targeted prevention strategies, particularly for younger populations who appear to be at the greatest risk.”
Received this email from a friend? Sign up here! ([link removed])
[link removed]

[link removed]
[link removed]
[link removed]
[link removed]
[link removed]

Smart Approaches to Marijuana (SAM) ([link removed]) is an alliance of organizations and individuals dedicated to a health-first approach to marijuana policy. We are professionals working in mental health and public health. We are bipartisan. We are medical doctors, lawmakers, treatment providers, preventionists, teachers, law enforcement officers and others who seek a middle road between incarceration and legalization. Our commonsense, third-way approach to marijuana policy is based on reputable science and sound principles of public health and safety.

Copyright (C) 2025 The Drug Report. All rights reserved.
You are receiving this email because you opted in at our website, gooddrugpolicy.org or through the Smart Approaches to Marijuana website, learnaboutsam.org.
Our mailing address is:
The Drug Report
107 S West St
Ste. 757
Alexandria, VA 22314
USA
Want to change how you receive these emails?
You can update your preferences ([link removed][UNIQID]&c=65f7be511c) or unsubscribe ([link removed][UNIQID]&c=65f7be511c)

This email was sent to [email protected] (mailto:[email protected])
why did I get this? ([link removed]) unsubscribe from this list ([link removed]) update subscription preferences ([link removed])
The Drug Report . 107 S West St . Ste. 757 . Alexandria, VA 22314 . USA